Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Sees Large Volume Increase – What’s Next?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) shares saw strong trading volume on Thursday . 1,288,843 shares traded hands during trading, an increase of 456% from the previous session’s volume of 231,617 shares.The stock last traded at $25.02 and had previously closed at $24.69.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. UBS Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They set a “buy” rating and a $45.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and issued a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price objective on the stock. Leerink Partners started coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, January 7th. They issued an “outperform” rating and a $46.00 price objective on the stock. Finally, Zacks Research raised Damora Therapeutics, Inc. Common Stock to a “hold” rating in a report on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $43.40.

Damora Therapeutics, Inc. Common Stock Trading Up 1.2%

The business has a 50-day moving average price of $26.42 and a two-hundred day moving average price of $23.40. The stock has a market capitalization of $1.51 billion, a P/E ratio of -2.07 and a beta of 1.50.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of institutional investors have recently modified their holdings of DMRA. Janus Henderson Group PLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $40,000. Virtu Financial LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at $49,000. Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at $76,000. Connective Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at $100,000. Finally, Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $266,000. 14.20% of the stock is currently owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.